Benfotiamine

Benfotiamine is a fat-soluble thiamine analogue that effectively raises intracellular thiamine diphosphate levels, showing promise in reducing advanced glycation end-products (AGEs) and symptoms of diabetic neuropathy, as well as potentially aiding in cognitive decline associated with Alzheimer's disease.

neuroprotectionanti-aginganti-diabeticneurologicalantioxidant

Evidence last reviewed: 20 Apr 2026

Buy this ingredient ← Back

Supplement note

Private note on this supplement

Save how you reacted, what dose worked, what to watch for, or anything you want to remember later in your Notes tab.

Biomarkers studied

Outcomes directly measured across the evidence records below

Cognitive

Cognitive FunctionNeuroprotection / NGF

Evidence

4 records

Cognitive function in Alzheimer's disease

Patients with Alzheimer's disease • RCT

PUBMEDLow

Benfotiamine treatment showed a trend towards improved cognitive outcomes, though not statistically significant.

Dose: 300 mgDuration: 12 monthsForm: Capsule

Citation: Gibson et al. (2020). Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial.

Cognitive decline in Alzheimer's disease

Patients with mild cognitive impairment or mild dementia due to Alzheimer's disease • RCT

PUBMEDModerate

Benfotiamine treatment resulted in a 43% lower increase in ADAS-Cog scores, indicating less cognitive decline, and significantly reduced AGE levels.

Dose: 300 mgDuration: 12 monthsForm: Capsule

Citation: Stirban et al. (2013). Variability of skin autofluorescence measurement over 6 and 12 weeks and the influence of benfotiamine treatment. NEJM.

Effect was stronger in APOE ε4 non-carriers.

Diabetic neuropathy symptoms

Patients with diabetic polyneuropathy • RCT

PUBMEDModerate

Benfotiamine showed potential efficacy in reducing symptoms of diabetic neuropathy.

Dose: 300 mgDuration: 3 weeksForm: Tablet

Citation: Haupt et al. (2005). Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study).

Advanced glycation end-products (AGEs) reduction

Type 2 diabetes patients with symptomatic polyneuropathy • RCT

PUBMEDModerate

Benfotiamine significantly reduced AGE levels, which are linked to diabetes complications.

Dose: 300 mgDuration: 12 monthsForm: Capsule

Citation: Ziegler et al. (2026). Effects of benfotiamine treatment over 12 months on morphometric, neurophysiological and clinical measures in type 2 diabetes patients with symptomatic polyneuropathy: a randomized, placebo-controlled, double-blind clinical trial (BOND study).

Forms

Capsule

Commonly used for oral supplementation.

Tablet

Alternative oral form, similar efficacy to capsules.

Stacks containing Benfotiamine

Public community stacks that include this ingredient.

Explore all stacks →

No public stacks include this ingredient yet.